3/13/2020 12:22:46 PM - Reported Dec '19 quarterly results -30% on -11% sales revenues. Consolidated in a tight range near its high since noted in the 12/26/19 mid-day report - "Reported +46% earnings on +14% sales revenues for the Sep '19 quarter, but prior quarters were not strong and steady above the +25% minimum (C criteria).Up and down annual earnings (A criteria) remain a concern. This Chinese Biomed firm completed Secondary Offerings on 3/02/16 and 6/03/16 after new Public Offerings on 6/10/15 and 6/27/14."

3/11/2020 12:31:29 PM - Due to report Dec '19 quarterly results on 3/12/20. Still consolidating in a tight range near its high since noted in the 12/26/19 mid-day report - "Reported +46% earnings on +14% sales revenues for the Sep '19 quarter, but prior quarters were not strong and steady above the +25% minimum (C criteria).Up and down annual earnings (A criteria) remain a concern. This Chinese Biomed firm completed Secondary Offerings on 3/02/16 and 6/03/16 after new Public Offerings on 6/10/15 and 6/27/14."

3/10/2020 12:24:02 PM - Due to report Dec '19 quarterly results on 3/12/20. Still consolidating in a tight range near its high since noted in the 12/26/19 mid-day report - "Reported +46% earnings on +14% sales revenues for the Sep '19 quarter, but prior quarters were not strong and steady above the +25% minimum (C criteria).Up and down annual earnings (A criteria) remain a concern. This Chinese Biomed firm completed Secondary Offerings on 3/02/16 and 6/03/16 after new Public Offerings on 6/10/15 and 6/27/14."

2/12/2020 12:13:29 PM - Still consolidating in a tight range near its high since noted in the 12/26/19 mid-day report - "Reported +46% earnings on +14% sales revenues for the Sep '19 quarter, but prior quarters were not strong and steady above the +25% minimum (C criteria).Up and down annual earnings (A criteria) remain a concern. This Chinese Biomed firm completed Secondary Offerings on 3/02/16 and 6/03/16 after new Public Offerings on 6/10/15 and 6/27/14."

2/4/2020 11:57:22 AM - Still consolidating in a tight range near its high since noted in the 12/26/19 mid-day report - "Reported +46% earnings on +14% sales revenues for the Sep '19 quarter, but prior quarters were not strong and steady above the +25% minimum (C criteria).Up and down annual earnings (A criteria) remain a concern. This Chinese Biomed firm completed Secondary Offerings on 3/02/16 and 6/03/16 after new Public Offerings on 6/10/15 and 6/27/14."

1/31/2020 12:54:31 PM - Still consolidating in a tight range near its high since noted in the 12/26/19 mid-day report - "Reported +46% earnings on +14% sales revenues for the Sep '19 quarter, but prior quarters were not strong and steady above the +25% minimum (C criteria).Up and down annual earnings (A criteria) remain a concern. This Chinese Biomed firm completed Secondary Offerings on 3/02/16 and 6/03/16 after new Public Offerings on 6/10/15 and 6/27/14."

1/24/2020 12:15:09 PM - Still consolidating in a tight range near its high since noted in the 12/26/19 mid-day report - "Reported +46% earnings on +14% sales revenues for the Sep '19 quarter, but prior quarters were not strong and steady above the +25% minimum (C criteria).Up and down annual earnings (A criteria) remain a concern. This Chinese Biomed firm completed Secondary Offerings on 3/02/16 and 6/03/16 after new Public Offerings on 6/10/15 and 6/27/14."

1/23/2020 12:58:14 PM - Still consolidating in a tight range near its high since noted in the 12/26/19 mid-day report - "Reported +46% earnings on +14% sales revenues for the Sep '19 quarter, but prior quarters were not strong and steady above the +25% minimum (C criteria).Up and down annual earnings (A criteria) remain a concern. This Chinese Biomed firm completed Secondary Offerings on 3/02/16 and 6/03/16 after new Public Offerings on 6/10/15 and 6/27/14."

1/16/2020 12:13:30 PM - Still consolidating in a tight range near its high since noted in the 12/26/19 mid-day report - "Reported +46% earnings on +14% sales revenues for the Sep '19 quarter, but prior quarters were not strong and steady above the +25% minimum (C criteria).Up and down annual earnings (A criteria) remain a concern. This Chinese Biomed firm completed Secondary Offerings on 3/02/16 and 6/03/16 after new Public Offerings on 6/10/15 and 6/27/14."

1/15/2020 12:47:18 PM - Still consolidating in a tight range near its high since noted in the 12/26/19 mid-day report - "Reported +46% earnings on +14% sales revenues for the Sep '19 quarter, but prior quarters were not strong and steady above the +25% minimum (C criteria).Up and down annual earnings (A criteria) remain a concern. This Chinese Biomed firm completed Secondary Offerings on 3/02/16 and 6/03/16 after new Public Offerings on 6/10/15 and 6/27/14."

1/14/2020 12:12:11 PM - Still consolidating in a tight range near its high since noted in the 12/26/19 mid-day report - "Reported +46% earnings on +14% sales revenues for the Sep '19 quarter, but prior quarters were not strong and steady above the +25% minimum (C criteria).Up and down annual earnings (A criteria) remain a concern. This Chinese Biomed firm completed Secondary Offerings on 3/02/16 and 6/03/16 after new Public Offerings on 6/10/15 and 6/27/14."

1/13/2020 12:42:31 PM - Still consolidating in a tight range near its high since noted in the 12/26/19 mid-day report - "Reported +46% earnings on +14% sales revenues for the Sep '19 quarter, but prior quarters were not strong and steady above the +25% minimum (C criteria).Up and down annual earnings (A criteria) remain a concern. This Chinese Biomed firm completed Secondary Offerings on 3/02/16 and 6/03/16 after new Public Offerings on 6/10/15 and 6/27/14."

1/7/2020 12:29:35 PM - Still consolidating in a tight range near its high since last noted in the 12/26/19 mid-day report - "Reported +46% earnings on +14% sales revenues for the Sep '19 quarter, but prior quarters were not strong and steady above the +25% minimum (C criteria).Up and down annual earnings (A criteria) remain a concern. This Chinese Biomed firm completed Secondary Offerings on 3/02/16 and 6/03/16 after new Public Offerings on 6/10/15 and 6/27/14."

12/26/2019 11:52:17 AM - Reported +46% earnings on +14% sales revenues for the Sep '19 quarter, but prior quarters were not strong and steady above the +25% minimum (C criteria).Up and down annual earnings (A criteria) remain a concern. This Chinese Biomed firm completed Secondary Offerings on 3/02/16 and 6/03/16 after new Public Offerings on 6/10/15 and 6/27/14.

12/13/2019 12:16:48 PM - Reported +46% earnings on +14% sales revenues for the Sep '19 quarter, but prior quarters were not strong and steady above the +25% minimum (C criteria).Up and down annual earnings (A criteria) remain a concern. This Chinese Biomed firm completed Secondary Offerings on 3/02/16 and 6/03/16 after new Public Offerings on 6/10/15 and 6/27/14.

4/26/2016 12:18:02 PM - This Chinese Biomed firm completed a Secondary Offering on 3/02/16 and new Public Offerings on 6/10/15 and 6/27/14. Reported +32% earnings on +18% sales revenues for the Dec '15 quarter, but prior quarters were not strong and steady above the +25% minimum (C criteria). Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving.

1/27/2016 12:09:32 PM - Finding support near its 50 DMA line and prior highs. Prior mid-day reports repeatedly cautioned members - "This Chinese Biomed firm completed new Public Offerings on 6/10/15 and 6/27/14. Reported +16% earnings on +14% sales revenues for the Sep '15 quarter, below the +25% minimum (C criteria). Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving."

1/6/2016 12:42:08 PM - Abruptly retreating from its 52-week high with 2 consecutive volume-driven losses following an impressive streak of gains. Prior mid-day reports repeatedly cautioned members - "This Chinese Biomed firm completed new Public Offerings on 6/10/15 and 6/27/14. Reported +16% earnings on +14% sales revenues for the Sep '15 quarter, below the +25% minimum (C criteria). Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving."

12/24/2015 11:03:56 AM - Hitting yet another new 52-week high while adding to a streak of gains backed by above average volume. Prior mid-day reports repeatedly cautioned members - "This Chinese Biomed firm completed new Public Offerings on 6/10/15 and 6/27/14. Reported +16% earnings on +14% sales revenues for the Sep '15 quarter, below the +25% minimum (C criteria). Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving."

12/23/2015 12:34:16 PM - Hitting another new 52-week high today while adding to a streak of gains backed by above average volume. Prior mid-day reports repeatedly cautioned members - "This Chinese Biomed firm completed new Public Offerings on 6/10/15 and 6/27/14. Reported +16% earnings on +14% sales revenues for the Sep '15 quarter, below the +25% minimum (C criteria). Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving."

12/22/2015 12:21:26 PM - Perched it 52-week high following a streak of gains backed by above average volume. Prior mid-day reports repeatedly cautioned members - "This Chinese Biomed firm completed new Public Offerings on 6/10/15 and 6/27/14. Reported +16% earnings on +14% sales revenues for the Sep '15 quarter, below the +25% minimum (C criteria). Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving."

12/21/2015 12:19:36 PM - Perched it 52-week high following a streak of gains backed by above average volume. Prior mid-day reports repeatedly cautioned members - "This Chinese Biomed firm completed new Public Offerings on 6/10/15 and 6/27/14. Reported +16% earnings on +14% sales revenues for the Sep '15 quarter, below the +25% minimum (C criteria). Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving."

12/17/2015 12:25:13 PM - Perched at a new 52-week high following a streak of gains backed by above average volume. Prior mid-day reports repeatedly cautioned members - "This Chinese Biomed firm completed new Public Offerings on 6/10/15 and 6/27/14. Reported +16% earnings on +14% sales revenues for the Sep '15 quarter, below the +25% minimum (C criteria). Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving."

12/16/2015 12:13:04 PM - Hit new 52-week highs with a streak of gains backed by above average volume. Prior mid-day reports repeatedly cautioned members - "This Chinese Biomed firm completed new Public Offerings on 6/10/15 and 6/27/14. Reported +16% earnings on +14% sales revenues for the Sep '15 quarter, below the +25% minimum (C criteria). Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving."

12/15/2015 12:17:34 PM - Challenging its 52-week high with a streak of gains backed by volume. Prior mid-day reports repeatedly cautioned members - "This Chinese Biomed firm completed new Public Offerings on 6/10/15 and 6/27/14. Reported +16% earnings on +14% sales revenues for the Sep '15 quarter, below the +25% minimum (C criteria). Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving."

12/14/2015 12:23:00 PM - Holding its ground near its 52-week high. Prior mid-day reports repeatedly cautioned members - "This Chinese Biomed firm completed new Public Offerings on 6/10/15 and 6/27/14. Reported +16% earnings on +14% sales revenues for the Sep '15 quarter, below the +25% minimum (C criteria). Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving."

11/27/2015 11:03:24 AM - Challenging its 52-week high. Prior mid-day reports repeatedly cautioned members - "This Chinese Biomed firm completed new Public Offerings on 6/10/15 and 6/27/14. Reported +16% earnings on +14% sales revenues for the Sep '15 quarter, below the +25% minimum (C criteria). Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving."

11/17/2015 12:15:48 PM - Challenging its 52-week high. Prior mid-day reports repeatedly cautioned members - "This Chinese Biomed firm completed new Public Offerings on 6/10/15 and 6/27/14. Reported +16% earnings on +14% sales revenues for the Sep '15 quarter, below the +25% minimum (C criteria). Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving."

11/13/2015 12:28:35 PM - Perched within striking distance of its 52-week high. Prior mid-day reports cautioned members - "This Chinese Biomed firm completed new Public Offerings on 6/10/15 and 6/27/14. Reported +16% earnings on +14% sales revenues for the Sep '15 quarter, below the +25% minimum (C criteria). Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving."

11/11/2015 12:28:15 PM - Consolidating above its 50 and 200 DMA lines, perched within striking distance of its 52-week high. This Chinese Biomed firm completed new Public Offerings on 6/10/15 and 6/27/14. Reported +16% earnings on +14% sales revenues for the Sep '15 quarter, below the +25% minimum (C criteria). Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving.

11/3/2015 12:24:59 PM - Consolidating above its 50 and 200 DMA lines, perched within striking distance of its 52-week high. This Chinese Biomed firm completed new Public Offerings on 6/10/15 and 6/27/14. Reported +29% earnings on +32% sales revenues for the Jun '15 quarter and prior earnings increases have been above the +25% minimum (C criteria). Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving.

8/19/2015 12:15:48 PM - Slumped below its 50 DMA line with volume-driven losses after wedging to new 52-week highs. This Chinese Biomed firm completed a new Public Offering on 6/10/15 and an earlier Public Offering on 6/27/14. Reported +29% earnings on +32% sales revenues for the Jun '15 quarter and prior earnings increases have been above the +25% minimum (C criteria). Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving.

6/18/2015 12:15:17 PM - Extended from any sound base, consolidating after finding prompt support near its 50 DMA line and rebounding near its 52-week high. This Chinese Biomed firm completed a new Public Offering on 6/10/15 and an earlier Public Offering on 6/27/14. Reported +29% earnings on +25% sales revenues for the Mar '15 quarter and prior earnings increases have been above the +25% minimum (C criteria). Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving.

6/17/2015 12:26:33 PM - Extended from any sound base, rebounding after finding prompt support near its 50 DMA line and completing an new Public Offering on 6/10/15. This Chinese Biomed firm completed an earlier Public Offering on 6/27/14. Reported +29% earnings on +25% sales revenues for the Mar '15 quarter and prior earnings increases have been above the +25% minimum (C criteria). Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving.

6/16/2015 12:21:10 PM - Chinese Biomed firm abruptly pulled back from its 52-week high after proposing a new Public Offering on 6/05/15. Found support at its 50 DMA line and completed the offering on 6/10/15. Completed an earlier Public Offering on 6/27/14. It is very extended from any sound base, and tallied big gains after technically breaking out from a "late-stage" base on 2/17/15. Reported +29% earnings on +25% sales revenues for the Mar '15 quarter and prior earnings increases have been above the +25% minimum (C criteria). Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving.

6/10/2015 1:01:17 PM -

Pulled back from its 52-week high after proposing a new Public Offering on 6/05/15. It is extended from any sound base. Made steady progress after technically breaking out from a "late-stage" base on 2/17/15. Reported +29% earnings on +25% sales revenues for the Mar '15 quarter and prior earnings increases have been above the +25% minimum (C criteria). Completed an earlier Public Offering on 6/27/14. Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving.



6/8/2015 12:07:35 PM -

Pulling back from its 52-week high with today's 3rd consecutive loss. Extended from any sound base, it made steady progress after technically breaking out from a "late-stage" base on 2/17/15. Reported +29% earnings on +25% sales revenues for the Mar '15 quarter and prior earnings increases have been above the +25% minimum (C criteria). Completed a new Public Offering on 6/27/14. Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving.



4/20/2015 12:20:38 PM -

Still perched near its 52-week high today, very extended from any sound base. Made steady progress after technically breaking out from a "late-stage" base on 2/17/15. Reported +60% earnings on +36% sales revenues for the Dec '14 quarter and prior earnings increases have been above the +25% minimum (C criteria). Completed a new Public Offering on 6/27/14. Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving.



4/16/2015 12:06:40 PM -

Still perched at its 52-week high today, very extended from any sound base. Made steady progress after technically breaking out from a "late-stage" base on 2/17/15. Reported +60% earnings on +36% sales revenues for the Dec '14 quarter and prior earnings increases have been above the +25% minimum (C criteria). Completed a new Public Offering on 6/27/14. Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving.



4/15/2015 12:11:14 PM -

Still perched at its 52-week high today, very extended from any sound base. Made steady progress after technically breaking out from a "late-stage" base on 2/17/15. Reported +60% earnings on +36% sales revenues for the Dec '14 quarter and prior earnings increases have been above the +25% minimum (C criteria). Completed a new Public Offering on 6/27/14. Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving.



4/14/2015 12:40:41 PM -

Perched at its 52-week high today, very extended from any sound base. Made steady progress after technically breaking out from a "late-stage" base on 2/17/15. Reported +60% earnings on +36% sales revenues for the Dec '14 quarter and prior earnings increases have been above the +25% minimum (C criteria). Completed a new Public Offering on 6/27/14. Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving.



4/13/2015 12:06:52 PM -

Hitting a new 52-week high today, very extended from any sound base. Made steady progress after technically breaking out from a "late-stage" base on 2/17/15. Reported +60% earnings on +36% sales revenues for the Dec '14 quarter and prior earnings increases have been above the +25% minimum (C criteria). Completed a new Public Offering on 6/27/14. Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving.



3/10/2015 12:15:11 PM -

Hovering near its 52-week high following a streak of volume-driven gains, extended after technically breaking out from a riskier "late-stage" base. Reported +60% earnings on +36% sales revenues for the Dec '14 quarter and prior earnings increases have been above the +25% minimum (C criteria). Completed a new Public Offering on 6/27/14. Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving.



3/6/2015 12:00:36 PM -

Hitting new 52-week highs again today after 4 consecutive gains, getting extended after technically breaking out from a riskier "late-stage" base. Reported +60% earnings on +36% sales revenues for the Dec '14 quarter and prior earnings increases have been above the +25% minimum (C criteria). Completed a new Public Offering on 6/27/14. Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving.



3/5/2015 12:43:05 PM -

Wedging to new 52-week highs with a streak of small gains lacking great volume conviction. Getting extended after technically breaking out from a riskier "late-stage" base. Reported +60% earnings on +36% sales revenues for the Dec '14 quarter and prior earnings increases have been above the +25% minimum (C criteria). Completed a new Public Offering on 6/27/14. Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving.



2/24/2015 12:31:38 PM -

Pulling back from its 52-week high after technically breaking out from a riskier "late-stage" base. Due to report Dec '14 earnings on 3/04/15 after the close. While finding support near its 50 DMA line prior mid-day reports cautioned members - "Reported earnings +45% on +30% sales revenues for the Sep '14 quarter, and earnings increases have been near or above the +25% minimum (C criteria). Completed a new Public Offering on 6/27/14. Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving."



2/19/2015 12:38:08 PM -

Powering to a new 52-week high, making its 3rd consecutive mid-day report appearance, technically breaking out from a riskier "late-stage" base with another big volume-driven gain. Due to report Dec '14 earnings on 3/04/15 after the close. While finding support near its 50 DMA line prior mid-day reports cautioned members - "Reported earnings +45% on +30% sales revenues for the Sep '14 quarter, and earnings increases have been near or above the +25% minimum (C criteria). Completed a new Public Offering on 6/27/14. Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving."



2/18/2015 12:04:30 PM -

Pulling back today after hitting a new 52-week high, technically breaking out from a riskier "late-stage" base with a big volume-driven gain on the prior session. Due to report Dec '14 earnings on 3/04/15 after the close. While finding support near its 50 DMA line prior mid-day reports cautioned members - "Reported earnings +45% on +30% sales revenues for the Sep '14 quarter, and earnings increases have been near or above the +25% minimum (C criteria). Completed a new Public Offering on 6/27/14. Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving."



2/17/2015 12:17:53 PM -

Hitting a new 52-week high, technically breaking out from a riskier "late-stage" base with today's big gain. Due to report Dec '14 earnings on 3/04/15 after the close. While finding support near its 50 DMA line prior mid-day reports cautioned members - "Reported earnings +45% on +30% sales revenues for the Sep '14 quarter, and earnings increases have been near or above the +25% minimum (C criteria). Completed a new Public Offering on 6/27/14. Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving."



2/13/2015 12:30:16 PM -

Still holding its ground in a tight trading range, consolidating near its 52-week high and finding support near its 50 DMA line. Prior mid-day reports cautioned members - "Reported earnings +45% on +30% sales revenues for the Sep '14 quarter, and earnings increases have been near or above the +25% minimum (C criteria). Completed a new Public Offering on 6/27/14. Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving."



2/10/2015 12:20:37 PM -

Still holding its ground in a tight trading range, consolidating near its 52-week high and finding support near its 50 DMA line. Prior mid-day reports cautioned members - "Reported earnings +45% on +30% sales revenues for the Sep '14 quarter, and earnings increases have been near or above the +25% minimum (C criteria). Completed a new Public Offering on 6/27/14. Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving."



2/9/2015 12:15:52 PM -

Still holding its ground in a tight trading range, consolidating near its 52-week high and finding support near its 50 DMA line. Prior mid-day reports cautioned members - "Reported earnings +45% on +30% sales revenues for the Sep '14 quarter, and earnings increases have been near or above the +25% minimum (C criteria). Completed a new Public Offering on 6/27/14. Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving."



2/6/2015 12:11:59 PM -

Still holding its ground in a tight trading range, consolidating near its 52-week high and finding support near its 50 DMA line. Prior mid-day reports cautioned members - "Reported earnings +45% on +30% sales revenues for the Sep '14 quarter, and earnings increases have been near or above the +25% minimum (C criteria). Completed a new Public Offering on 6/27/14. Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving."



2/5/2015 12:11:58 PM -

Still holding its ground in a tight trading range, consolidating near its 52-week high and finding support near its 50 DMA line. Prior mid-day reports cautioned members - "Reported earnings +45% on +30% sales revenues for the Sep '14 quarter, and earnings increases have been near or above the +25% minimum (C criteria). Completed a new Public Offering on 6/27/14. Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving."



1/30/2015 12:30:44 PM -

Encountering distributional pressure this week while still holding its ground in a tight trading range, consolidating near its 52-week high and finding support near its 50 DMA line. Reported earnings +45% on +30% sales revenues for the Sep '14 quarter, and earnings increases have been near or above the +25% minimum (C criteria). Completed a new Public Offering on 6/27/14. Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving.



1/28/2015 12:23:11 PM -

Still holding its ground in a tight trading range while consolidating near its 52-week high and finding support near its 50 DMA line. Reported earnings +45% on +30% sales revenues for the Sep '14 quarter, and earnings increases have been near or above the +25% minimum (C criteria). Completed a new Public Offering on 6/27/14. Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving.



1/26/2015 12:17:05 PM -

Still holding its ground in a tight trading range while consolidating near its 52-week high and finding support near its 50 DMA line. Reported earnings +45% on +30% sales revenues for the Sep '14 quarter, and earnings increases have been near or above the +25% minimum (C criteria). Completed a new Public Offering on 6/27/14. Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving.



1/22/2015 12:09:38 PM -

Holding its ground in a tight trading range while consolidating near its 52-week high and finding support near its 50 DMA line. Reported earnings +45% on +30% sales revenues for the Sep '14 quarter, and earnings increases have been near or above the +25% minimum (C criteria). Completed a new Public Offering on 6/27/14. Following a downturn in FY '10 earnings its annual earnings (A criteria) have been improving.



12/2/2014 12:19:22 PM -

Stubbornly holding its ground while recently consolidating near its 52-week high. Reported earnings +45% on +30% sales revenues for the Sep '14 quarter, but fundamental concerns remain. Volume-driven gains in an impressive spurt helped it rally clear of overhead supply from a riskier "late stage" base, however prior mid-day reports repeatedly cautioned members - "Completed a new Public Offering on 6/27/14. Reported earnings +32% on +12% sales revenues for the Jun '14 quarter, but fundamental concerns remain. Earnings increases have been near or above the +25% minimum (C criteria) guideline in the 3 latest quarterly comparisons, however a downturn in FY '10 earnings is a flaw concerning the A criteria."



11/28/2014 10:52:14 AM -

Endured some distributional pressure while recently consolidating near its 52-week high. Reported earnings +45% on +30% sales revenues for the Sep '14 quarter, but fundamental concerns remain. Volume-driven gains in an impressive spurt helped it rally clear of overhead supply from a riskier "late stage" base, however prior mid-day reports repeatedly cautioned members - "Completed a new Public Offering on 6/27/14. Reported earnings +32% on +12% sales revenues for the Jun '14 quarter, but fundamental concerns remain. Earnings increases have been near or above the +25% minimum (C criteria) guideline in the 3 latest quarterly comparisons, however a downturn in FY '10 earnings is a flaw concerning the A criteria."



11/21/2014 12:20:40 PM -

Endured some distributional pressure while recently consolidating near its 52-week high. Reported earnings +45% on +30% sales revenues for the Sep '14 quarter, but fundamental concerns remain. Volume-driven gains in an impressive spurt helped it rally clear of overhead supply from a riskier "late stage" base, however prior mid-day reports repeatedly cautioned members - "Completed a new Public Offering on 6/27/14. Reported earnings +32% on +12% sales revenues for the Jun '14 quarter, but fundamental concerns remain. Earnings increases have been near or above the +25% minimum (C criteria) guideline in the 3 latest quarterly comparisons, however a downturn in FY '10 earnings is a flaw concerning the A criteria."



11/19/2014 12:20:56 PM -

Enduring some distributional pressure for the past 2 weeks while consolidating near its 52-week high. Reported earnings +45% on +30% sales revenues for the Sep '14 quarter, but fundamental concerns remain. Volume-driven gains in an impressive spurt helped it rally clear of overhead supply from a riskier "late stage" base, however prior mid-day reports repeatedly cautioned members - "Completed a new Public Offering on 6/27/14. Reported earnings +32% on +12% sales revenues for the Jun '14 quarter, but fundamental concerns remain. Earnings increases have been near or above the +25% minimum (C criteria) guideline in the 3 latest quarterly comparisons, however a downturn in FY '10 earnings is a flaw concerning the A criteria."



11/18/2014 12:11:35 PM -

Hovering near its 52-week high, holding its ground after recent volume-driven losses. Reported earnings +45% on +30% sales revenues for the Sep '14 quarter, but fundamental concerns remain. Volume-driven gains in an impressive spurt helped it rally clear of overhead supply from a riskier "late stage" base, however prior mid-day reports repeatedly cautioned members - "Completed a new Public Offering on 6/27/14. Reported earnings +32% on +12% sales revenues for the Jun '14 quarter, but fundamental concerns remain. Earnings increases have been near or above the +25% minimum (C criteria) guideline in the 3 latest quarterly comparisons, however a downturn in FY '10 earnings is a flaw concerning the A criteria."



11/10/2014 12:17:58 PM -

Pulling back from its 52-week high with today's 2nd consecutive volume-driven loss. Reported earnings +45% on +30% sales revenues for the Sep '14 quarter, but fundamental concerns remain. Volume-driven gains in an impressive spurt helped it rally clear of overhead supply from a riskier "late stage" base, however prior mid-day reports repeatedly cautioned members - "Completed a new Public Offering on 6/27/14. Reported earnings +32% on +12% sales revenues for the Jun '14 quarter, but fundamental concerns remain. Earnings increases have been near or above the +25% minimum (C criteria) guideline in the 3 latest quarterly comparisons, however a downturn in FY '10 earnings is a flaw concerning the A criteria."



11/6/2014 12:14:17 PM -

Perched at its 52-week high today. Reported earnings +45% on +30% sales revenues for the Sep '14 quarter, but fundamental concerns remain. Volume-driven gains in an impressive spurt helped it rally clear of overhead supply from a riskier "late stage" base, however prior mid-day reports repeatedly cautioned members - "Completed a new Public Offering on 6/27/14. Reported earnings +32% on +12% sales revenues for the Jun '14 quarter, but fundamental concerns remain. Earnings increases have been near or above the +25% minimum (C criteria) guideline in the 3 latest quarterly comparisons, however a downturn in FY '10 earnings is a flaw concerning the A criteria."



11/4/2014 12:37:19 PM -

Hit yet another new 52-week high today then reversed into the red. Volume-driven gains in an impressive spurt helped it rally clear of overhead supply from a riskier "late stage" base, however prior mid-day reports repeatedly cautioned members - "Completed a new Public Offering on 6/27/14. Reported earnings +32% on +12% sales revenues for the Jun '14 quarter, but fundamental concerns remain. Earnings increases have been near or above the +25% minimum (C criteria) guideline in the 3 latest quarterly comparisons, however a downturn in FY '10 earnings is a flaw concerning the A criteria."



11/3/2014 12:10:35 PM -

Hitting yet another new 52-week high with today's volume-driven gain adding to an impressive spurt of gains. No resistance remains due to overhead supply, yet it is rallying from a riskier "late stage" base. Prior mid-day reports repeatedly cautioned members - "Completed a new Public Offering on 6/27/14. Reported earnings +32% on +12% sales revenues for the Jun '14 quarter, but fundamental concerns remain. Earnings increases have been near or above the +25% minimum (C criteria) guideline in the 3 latest quarterly comparisons, however a downturn in FY '10 earnings is a flaw concerning the A criteria."



10/30/2014 12:36:31 PM -

Hitting another new 52-week high with today's volume-driven gain. No resistance remains due to overhead supply, yet it is rallying from a riskier "late stage" base. Prior mid-day reports repeatedly cautioned members - "Completed a new Public Offering on 6/27/14. Reported earnings +32% on +12% sales revenues for the Jun '14 quarter, but fundamental concerns remain. Earnings increases have been near or above the +25% minimum (C criteria) guideline in the 3 latest quarterly comparisons, however a downturn in FY '10 earnings is a flaw concerning the A criteria."



10/27/2014 12:10:18 PM -

Hit a new 52-week high with today's 9th consecutive gain and no resistance remains due to overhead supply. Prior mid-day reports repeatedly cautioned members - "Completed a new Public Offering on 6/27/14. Reported earnings +32% on +12% sales revenues for the Jun '14 quarter, but fundamental concerns remain. Earnings increases have been near or above the +25% minimum (C criteria) guideline in the 3 latest quarterly comparisons, however a downturn in FY '10 earnings is a flaw concerning the A criteria."



10/24/2014 12:22:11 PM -

Perched within close striking distance of its 52-week high with today's 8th consecutive gain, facing very little resistance due to overhead supply. Prior mid-day reports cautioned members - "Completed a new Public Offering on 6/27/14. Reported earnings +32% on +12% sales revenues for the Jun '14 quarter, but fundamental concerns remain. Earnings increases have been near or above the +25% minimum (C criteria) guideline in the 3 latest quarterly comparisons, however a downturn in FY '10 earnings is a flaw concerning the A criteria."



10/22/2014 12:23:01 PM -

Challenging its 52-week high with today's 6th consecutive gain, facing very little resistance due to overhead supply. Completed a new Public Offering on 6/27/14. Reported earnings +32% on +12% sales revenues for the Jun '14 quarter, but fundamental concerns remain. Earnings increases have been near or above the +25% minimum (C criteria) guideline in the 3 latest quarterly comparisons, however a downturn in FY '10 earnings is a flaw concerning the A criteria.



9/23/2014 12:14:25 PM -

Still holding its ground stubbornly near its 52-week high since rallying clear of all resistance due to overhead supply when noted with caution in the 8/27/14 mid-day report - "Completed a new Public Offering on 6/27/14. Reported earnings +32% on +12% sales revenues for the Jun '14 quarter but fundamental concerns remain. Reported earnings +24% on +4% sales revenues for the Mar '14 quarter and fundamental concerns remain. Earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



9/22/2014 12:18:33 PM -

Holding its ground stubbornly near its 52-week high since rallying clear of all resistance due to overhead supply when noted with caution in the 8/27/14 mid-day report - "Completed a new Public Offering on 6/27/14. Reported earnings +32% on +12% sales revenues for the Jun '14 quarter but fundamental concerns remain. Reported earnings +24% on +4% sales revenues for the Mar '14 quarter and fundamental concerns remain. Earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



9/15/2014 12:20:52 PM -

Holding its ground near its 52-week high today following 3 consecutive gains. Held its ground stubbornly since rallying clear of all resistance due to overhead supply when last noted with caution in the 8/27/14 mid-day report - "Completed a new Public Offering on 6/27/14. Reported earnings +32% on +12% sales revenues for the Jun '14 quarter but fundamental concerns remain. Reported earnings +24% on +4% sales revenues for the Mar '14 quarter and fundamental concerns remain. Earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



8/27/2014 12:17:53 PM -

Hit another new 52-week high today then reversed into the red following a streak of 5 consecutive gains on ever-increasing volume rallying clear of all resistance due to overhead supply. Completed a new Public Offering on 6/27/14. Reported earnings +32% on +12% sales revenues for the Jun '14 quarter but fundamental concerns remain. Prior mid-day reports repeatedly cautioned members - "Reported earnings +24% on +4% sales revenues for the Mar '14 quarter and fundamental concerns remain. Earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



8/26/2014 12:08:46 PM -

Hitting a new 52-week high with today's 5th consecutive gain on ever-increasing volume, rallying clear of all resistance due to overhead supply. Completed a new Public Offering on 6/27/14. Reported earnings +32% on +12% sales revenues for the Jun '14 quarter but fundamental concerns remain. Prior mid-day reports repeatedly cautioned members - "Reported earnings +24% on +4% sales revenues for the Mar '14 quarter and fundamental concerns remain. Earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



7/9/2014 12:09:38 PM -

Rallied to a new 52-week high with a considerable volume-driven gain on the prior session. Rebounded above its 50 DMA line with a big volume-driven gain as it completed a new Public Offering on 6/27/14. Prior mid-day reports repeatedly cautioned members - "Reported earnings +24% on +4% sales revenues for the Mar '14 quarter and fundamental concerns remain. Earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



7/8/2014 12:41:33 PM -

Rallying within close striking distance of its 52-week high with a volume-driven gain. Rebounded above its 50 DMA line with a big volume-driven gain as it completed a new Public Offering on 6/27/14. Prior mid-day reports repeatedly cautioned members - "Reported earnings +24% on +4% sales revenues for the Mar '14 quarter and fundamental concerns remain. Earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



7/3/2014 11:00:05 AM -

Rallied within striking distance of its 52-week high with 4 consecutive gains. Rebounded above its 50 DMA line with a big volume-driven gain as it completed a new Public Offering on 6/27/14. Prior mid-day reports repeatedly cautioned members - "Reported earnings +24% on +4% sales revenues for the Mar '14 quarter and fundamental concerns remain. Earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



7/2/2014 12:19:25 PM -

Rallying within striking distance of its 52-week high with today's 4th consecutive gain. Rebounded above its 50 DMA line with a big volume-driven gain as it completed a new Public Offering on 6/27/14. Prior mid-day reports repeatedly cautioned members - "Reported earnings +24% on +4% sales revenues for the Mar '14 quarter and fundamental concerns remain. Earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



6/30/2014 11:56:08 AM -

Rebounded above its 50 DMA line with a big volume-driven gain as it completed a new Public Offering on 6/27/14. Prior mid-day reports repeatedly cautioned members - "Reported earnings +24% on +4% sales revenues for the Mar '14 quarter and fundamental concerns remain. Earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



6/23/2014 12:17:37 PM -

Touched a new 52-week high today but erased much of its early gain. Found support near its 50 DMA line during its recent consolidation and proposed a new Public Offering on 6/17/14. Prior mid-day reports repeatedly cautioned members - "Reported earnings +24% on +4% sales revenues for the Mar '14 quarter and fundamental concerns remain. Earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



6/13/2014 12:12:30 PM -

Perched at its 52-week high, holding its ground after volume-driven gains. Found support near its 50 DMA line during its recent consolidation. Prior mid-day reports repeatedly cautioned members - "Reported earnings +24% on +4% sales revenues for the Mar '14 quarter and fundamental concerns remain. Earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



6/10/2014 11:51:53 AM -

Perched at its 52-week high after volume-driven gains. Found support near its 50 DMA line during its recent consolidation. Prior mid-day reports cautioned members - "Reported earnings +24% on +4% sales revenues for the Mar '14 quarter and fundamental concerns remain. Earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



6/9/2014 12:16:27 PM -

Perched at its 52-week high after volume-driven gains. Found support near its 50 DMA line during its recent consolidation. Prior mid-day reports cautioned members - "Reported earnings +24% on +4% sales revenues for the Mar '14 quarter and fundamental concerns remain. Earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



6/5/2014 12:30:35 PM -

Hitting a new 52-week high with today's 2nd consecutive volume-driven gain. Found support near its 50 DMA line during its recent consolidation. Prior mid-day reports cautioned members - "Reported earnings +24% on +4% sales revenues for the Mar '14 quarter and fundamental concerns remain. Earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



6/4/2014 12:16:12 PM -

Holding its ground in a tight range near its 52-week high following volume-driven gains. Found support near its 50 DMA line during its recent consolidation. Prior mid-day reports cautioned members - "Reported earnings +24% on +4% sales revenues for the Mar '14 quarter and fundamental concerns remain. Earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



5/27/2014 12:18:34 PM -

Hitting another new 52-week high with today's 3rd consecutive volume-driven gain. Found support near its 50 DMA line during its recent consolidation. Prior mid-day reports cautioned members - "Reported earnings +24% on +4% sales revenues for the Mar '14 quarter and fundamental concerns remain. Earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



5/23/2014 12:04:53 PM -

Hitting another new 52-week high with today's 2nd consecutive volume-driven gain. Found support near its 50 DMA line during its recent consolidation. Prior mid-day reports cautioned members - "Reported earnings +24% on +4% sales revenues for the Mar '14 quarter and fundamental concerns remain. Earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



5/22/2014 12:08:26 PM -

Hovering near its 52-week high. Found support near its 50 DMA line during its recent consolidation. Prior mid-day reports cautioned members - "Reported earnings +24% on +4% sales revenues for the Mar '14 quarter and fundamental concerns remain. Earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



5/21/2014 12:10:45 PM -

Consolidating near its 52-week high. Found support near its 50 DMA line during its recent consolidation. Prior mid-day reports cautioned members - "Reported earnings +24% on +4% sales revenues for the Mar '14 quarter and fundamental concerns remain. Earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



5/19/2014 12:12:30 PM -

Touched a new 52-week high today. Found support near its 50 DMA line during its recent consolidation. Prior mid-day reports cautioned members - "Reported earnings +24% on +4% sales revenues for the Mar '14 quarter and fundamental concerns remain. Earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



5/15/2014 12:14:33 PM -

Still perched near its 52-week high, it found support near its 50 DMA line during its recent consolidation. Reported earnings +24% on +4% sales revenues for the Mar '14 quarter and fundamental concerns remain. Prior reports cautioned members - "Earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



5/14/2014 12:16:00 PM -

Perched near its 52-week high, it found support near its 50 DMA line during its recent consolidation. Reported earnings +24% on +4% sales revenues for the Mar '14 quarter and fundamental concerns remain. Prior reports cautioned members - "Earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



5/13/2014 12:29:01 PM -

Perched near its 52-week high, it found support near its 50 DMA line during its recent consolidation. Reported earnings +24% on +4% sales revenues for the Mar '14 quarter and fundamental concerns remain. Prior reports cautioned members - "Earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



5/12/2014 12:08:53 PM -

Found support near its 50 DMA line during its recent consolidation. Reported earnings +24% on +4% sales revenues for the Mar '14 quarter and fundamental concerns remain. Prior reports cautioned members - "Earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



5/9/2014 12:23:47 PM -

Found support at its 50 DMA line this week. Reported earnings +24% on +4% sales revenues for the Mar '14 quarter and fundamental concerns remain. Prior reports cautioned members - "Earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



5/8/2014 11:52:48 AM -

Undercut its 50 DMA line today then rebounded from early lows back into positive ground. Reported earnings +24% on +4% sales revenues for the Mar '14 quarter and fundamental concerns remain. Prior reports cautioned members - "Earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



5/1/2014 11:48:02 AM -

Pulling back since last noted in the 4/24/14 mid-day report, finding support at its 50 DMA line. Reported earnings +30% on +25% sale revenues for the Dec '13 quarter but fundamental concerns remain. Prior reports cautioned members - "Reported earnings +4% on +0% sales for the Sep 13 quarter, and earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



4/24/2014 12:17:01 PM -

Hovering near its 52-week high today after 7 consecutive gains and rallying from an orderly base with heavy volume. Found support above prior highs and near its 50 DMA line during its recent consolidation. Reported earnings +30% on +25% sale revenues for the Dec '13 quarter but fundamental concerns remain. Prior reports cautioned members - "Reported earnings +4% on +0% sales for the Sep 13 quarter, and earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



4/23/2014 12:44:23 PM -

Hitting a new 52-week high with above average volume behind today's 7th consecutive gain, rallying from an orderly base. Found support above prior highs and near its 50 DMA line during its recent consolidation. Reported earnings +30% on +25% sale revenues for the Dec '13 quarter but fundamental concerns remain. Prior reports cautioned members - "Reported earnings +4% on +0% sales for the Sep 13 quarter, and earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



4/16/2014 12:06:44 PM -

Reported earnings +30% on +25% sale revenues for the Dec '13 quarter but fundamental concerns remain. Found support above prior highs and near its 50 DMA line since noted in the 3/03/14 mid-day report. Prior reports cautioned members - "Reported earnings +4% on +0% sales for the Sep 13 quarter, and earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



3/26/2014 12:26:41 PM -

Reported earnings +30% on +25% sale revenues for the Dec '13 quarter but fundamental concerns remain. Found support above prior highs and near its 50 DMA line since last noted in the 3/03/14 mid-day report, consolidating since spiking to new 52-week highs with volume-driven gains. Found support near its 200 DMA line after noted with caution in the 12/12/13 mid-day report - "Reported earnings +4% on +0% sales for the Sep 13 quarter, and earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



3/3/2014 12:15:06 PM -

Challenging its 52-week high with today's gain. Found support near its 200 DMA line while consolidating since noted with caution in the 12/12/13 mid-day report - "Reported earnings +4% on +0% sales for the Sep 13 quarter, and earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



2/24/2014 12:13:44 PM -

Retreating from its 52-week high hit last week with considerable volume-driven gains. Found support near its 200 DMA line while consolidating since noted with caution in the 12/12/13 mid-day report - "Reported earnings +4% on +0% sales for the Sep 13 quarter, and earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



2/20/2014 12:16:12 PM -

Hitting new 52-week highs with considerable volume-driven gains. Found support near its 200 DMA line while consolidating since last noted with caution in the 12/12/13 mid-day report - "Reported earnings +4% on +0% sales for the Sep 13 quarter, and earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



12/12/2013 12:27:21 PM -

Rallying near its 50 DMA line with a volume-driven gain after recently slumping under that important short-term average. Prior mid-day reports repeatedly cautioned members - "Reported earnings +4% on +0% sales for the Sep 13 quarter, and earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."



11/22/2013 12:11:12 PM - Still consolidating above its 50 DMA line and in a tight range near its 52-week high. Prior mid-day reports repeatedly cautioned members - "Reported earnings +4% on +0% sales for the Sep 13 quarter, and earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria."

11/20/2013 12:18:04 PM - Above its 50 DMA line and still perched near its 52-week high today after choppy consolidation since noted in the 3/14/13 mid-day report with caution. Reported earnings +4% on +0% sales for the Sep 13 quarter, and earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria.

11/18/2013 12:18:45 PM - Perched near its 52-week high today after choppy consolidation since noted in the 3/14/13 mid-day report with caution. Reported earnings +4% on +0% sales for the Sep 13 quarter, and earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria.

11/14/2013 12:17:04 PM - Perched near its 52-week high today after choppy consolidation since last noted in the 3/14/13 mid-day report with caution. Reported earnings +4% on +0% sales for the Sep 13 quarter, and earnings increases have been below the +25% minimum necessary to satisfy the C criteria. Waning annual earnings increases in FY '10 and '11 were noted as a flaw concerning the A criteria.

3/14/2013 12:11:05 PM - Perched near its 52-week high today after a streak of gains with above average volume. Reported earnings -18% on -5% sales revenues for the Dec '12 quarter. Held its ground stubbornly and rallied further since the 2/20/13 mid-day report cautioned - "Recent quarterly comparisons through Sep '12 satisfy the C criteria, but waning annual earnings increases in FY '10 and '11 are a flaw concerning the A criteria. It survived but failed to impress since noted in the 2/03/11 mid-day report - 'The China-based Medical - Biomed/Biotech firm has earned high ranks, but it sales and earnings increases have been erratic and below the fact-based investment system's guidelines.'"

3/12/2013 12:06:47 PM - Still perched at its 52-week high today and adding to a streak of gains with above average volume. Held its ground stubbornly and rallied further since the 2/20/13 mid-day report cautioned - "Recent quarterly comparisons through Sep '12 satisfy the C criteria, but waning annual earnings increases in FY '10 and '11 are a flaw concerning the A criteria. It survived but failed to impress since noted in the 2/03/11 mid-day report - 'The China-based Medical - Biomed/Biotech firm has earned high ranks, but it sales and earnings increases have been erratic and below the fact-based investment system's guidelines.'"

3/11/2013 12:09:17 PM - Perched at its 52-week high today and adding to a streak of gains with above average volume. Held its ground stubbornly and rallied further since the 2/20/13 mid-day report cautioned - "Recent quarterly comparisons through Sep '12 satisfy the C criteria, but waning annual earnings increases in FY '10 and '11 are a flaw concerning the A criteria. It survived but failed to impress since noted in the 2/03/11 mid-day report - 'The China-based Medical - Biomed/Biotech firm has earned high ranks, but it sales and earnings increases have been erratic and below the fact-based investment system's guidelines.'"

3/8/2013 12:08:05 PM - Perched at its 52-week high today after a streak of 4 consecutive gains with above average volume. Held its ground stubbornly and rallied further since the 2/20/13 mid-day report cautioned - "Recent quarterly comparisons through Sep '12 satisfy the C criteria, but waning annual earnings increases in FY '10 and '11 are a flaw concerning the A criteria. It survived but failed to impress since noted in the 2/03/11 mid-day report - 'The China-based Medical - Biomed/Biotech firm has earned high ranks, but it sales and earnings increases have been erratic and below the fact-based investment system's guidelines.'"

3/6/2013 12:03:17 PM - Hitting another new 52-week high with above average volume behind today's 3rd consecutive gain. Held its ground stubbornly and rallied further since the 2/20/13 mid-day report cautioned - "Recent quarterly comparisons through Sep '12 satisfy the C criteria, but waning annual earnings increases in FY '10 and '11 are a flaw concerning the A criteria. It survived but failed to impress since noted in the 2/03/11 mid-day report - 'The China-based Medical - Biomed/Biotech firm has earned high ranks, but it sales and earnings increases have been erratic and below the fact-based investment system's guidelines.'"

3/4/2013 12:09:31 PM - Hitting a new 52-week high with above average volume behind today's gain. While pulling back after rising from a short and orderly flat base pattern with a volume-driven gain the 2/20/13 mid-day report cautioned - "Recent quarterly comparisons through Sep '12 satisfy the C criteria, but waning annual earnings increases in FY '10 and '11 are a flaw concerning the A criteria. It survived but failed to impress since noted in the 2/03/11 mid-day report - 'The China-based Medical - Biomed/Biotech firm has earned high ranks, but it sales and earnings increases have been erratic and below the fact-based investment system's guidelines.'"

2/20/2013 11:59:56 AM - Pulling back today after hitting a new 52-week high with above average volume behind its considerable gain on the prior session when rising from a short and orderly flat base pattern. Prior mid-day reports cautioned - "Recent quarterly comparisons through Sep '12 satisfy the C criteria, but waning annual earnings increases in FY '10 and '11 are a flaw concerning the A criteria. It survived but failed to impress since noted in the 2/03/11 mid-day report - 'The China-based Medical - Biomed/Biotech firm has earned high ranks, but it sales and earnings increases have been erratic and below the fact-based investment system's guidelines.'"

2/19/2013 12:21:35 PM - Hit a new 52-week high with above average volume behind today's considerable gain. Rising from a short and orderly flat base pattern formed since last noted in the 1/15/13 mid-day report with caution - "Recent quarterly comparisons through Sep '12 satisfy the C criteria, but waning annual earnings increases in FY '10 and '11 are a flaw concerning the A criteria. It survived but failed to impress since noted in the 2/03/11 mid-day report - 'The China-based Medical - Biomed/Biotech firm has earned high ranks, but it sales and earnings increases have been erratic and below the fact-based investment system's guidelines.'"

1/15/2013 11:50:40 AM - Hitting yet another new 52-week high with above average volume behind today's 9th consecutive gain. Prior mid-day reports repeatedly cautioned - "It is extended from any sound base pattern following a recent spurt of volume-driven gains. Recent quarterly comparisons through Sep '12 satisfy the C criteria, but waning annual earnings increases in FY '10 and '11 are a flaw concerning the A criteria. It survived but failed to impress since noted in the 2/03/11 mid-day report - 'The China-based Medical - Biomed/Biotech firm has earned high ranks, but it sales and earnings increases have been erratic and below the fact-based investment system's guidelines.'"

1/10/2013 12:02:30 PM - Hitting yet another new 52-week high with above average volume behind today's 6th consecutive gain. Prior mid-day reports repeatedly cautioned - "It is extended from any sound base pattern following a recent spurt of volume-driven gains. Recent quarterly comparisons through Sep '12 satisfy the C criteria, but waning annual earnings increases in FY '10 and '11 are a flaw concerning the A criteria. It survived but failed to impress since noted in the 2/03/11 mid-day report - 'The China-based Medical - Biomed/Biotech firm has earned high ranks, but it sales and earnings increases have been erratic and below the fact-based investment system's guidelines.'"

12/28/2012 12:16:33 PM - Hitting another new 52-week high today with a 2nd consecutive volume-driven gain. Prior mid-day reports repeatedly noted - "It is extended from any sound base pattern following a recent spurt of volume-driven gains. Recent quarterly comparisons through Sep '12 satisfy the C criteria, but waning annual earnings increases in FY '10 and '11 are a flaw concerning the A criteria. It survived but failed to impress since noted in the 2/03/11 mid-day report - 'The China-based Medical - Biomed/Biotech firm has earned high ranks, but it sales and earnings increases have been erratic and below the fact-based investment system's guidelines.'"

12/27/2012 12:05:33 PM - Hit a new 52-week high today with a volume-driven gain. Prior mid-day reports repeatedly noted - "It is extended from any sound base pattern following a recent spurt of volume-driven gains. Recent quarterly comparisons through Sep '12 satisfy the C criteria, but waning annual earnings increases in FY '10 and '11 are a flaw concerning the A criteria. It survived but failed to impress since noted in the 2/03/11 mid-day report - 'The China-based Medical - Biomed/Biotech firm has earned high ranks, but it sales and earnings increases have been erratic and below the fact-based investment system's guidelines.'"

12/24/2012 10:54:59 AM - Still hovering near its 52-week high. Prior mid-day reports repeatedly noted - "It is extended from any sound base pattern following a recent spurt of volume-driven gains. Recent quarterly comparisons through Sep '12 satisfy the C criteria, but waning annual earnings increases in FY '10 and '11 are a flaw concerning the A criteria. It survived but failed to impress since noted in the 2/03/11 mid-day report - 'The China-based Medical - Biomed/Biotech firm has earned high ranks, but it sales and earnings increases have been erratic and below the fact-based investment system's guidelines.'"

12/18/2012 12:00:42 PM - Trading above average volume, churning and still hovering near its 52-week high. Prior mid-day reports noted - "It is extended from any sound base pattern following a recent spurt of volume-driven gains. Recent quarterly comparisons through Sep '12 satisfy the C criteria, but waning annual earnings increases in FY '10 and '11 are a flaw concerning the A criteria. It survived but failed to impress since noted in the 2/03/11 mid-day report - 'The China-based Medical - Biomed/Biotech firm has earned high ranks, but it sales and earnings increases have been erratic and below the fact-based investment system's guidelines.'"

12/14/2012 12:11:34 PM - Hovering near its 52-week high. The 12/12/12 mid-day report noted - "It is extended from any sound base pattern following a recent spurt of volume-driven gains. Recent quarterly comparisons through Sep '12 satisfy the C criteria, but waning annual earnings increases in FY '10 and '11 are a flaw concerning the A criteria. It survived but failed to impress since noted in the 2/03/11 mid-day report - 'The China-based Medical - Biomed/Biotech firm has earned high ranks, but it sales and earnings increases have been erratic and below the fact-based investment system's guidelines.'"

12/12/2012 12:03:16 PM - Today's volume-driven gain has it challenging its 52-week high. It is extended from any sound base pattern following a recent spurt of volume-driven gains. Recent quarterly comparisons through Sep '12 satisfy the C criteria, but waning annual earnings increases in FY '10 and '11 are a flaw concerning the A criteria. It survived but failed to impress since noted in the 2/03/11 mid-day report - "The China-based Medical - Biomed/Biotech firm has earned high ranks, but it sales and earnings increases have been erratic and below the fact-based investment system's guidelines."

12/10/2012 12:12:46 PM - Considerable gain today has it challenging its 52-week high. Recent quarterly comparisons through Sep '12 satisfy the C criteria, but waning annual earnings increases in recent years are a flaw concerning the A criteria. It survived but failed to impress since last noted in the 2/03/11 mid-day report - "The China-based Medical - Biomed/Biotech firm has earned high ranks, but it sales and earnings increases have been erratic and below the fact-based investment system's guidelines."

2/3/2011 12:38:56 PM - Considerable gain today helped it hit a new high following an orderly base. Much as the case was when last noted in the mid-day report on 5/19/10, the China-based Medical - Biomed/Biotech firm has earned high ranks, but it sales and earnings increases have been erratic and below the fact-based investment system's guidelines.

5/19/2010 12:35:02 PM - Small gap up and gain today helped it hit a new high. Recently rallying above the high from when it was last noted in the mid-day report on 1/11/10. The China-based Medical - Biomed/Biotech firm has earned high ranks. For the quarter ended March 31, 2010 its sales and earnings increases were just above the +25% guideline after erratic prior comparisons which were mostly strong.

1/11/2010 12:43:53 PM - Gapped up today and hit a new high, extended from any sound base. Latest quarter and its annual earnings history are below guidelines.